Your browser doesn't support javascript.
loading
Long-term outcomes following first short-term clinically important deterioration in COPD.
Naya, Ian P; Tombs, Lee; Muellerova, Hana; Compton, Christopher; Jones, Paul W.
Afiliação
  • Naya IP; Respiratory Medicine, GSK, Brentford, Middlesex, UK. ian.p.naya@gsk.com.
  • Tombs L; Precise Approach Ltd, Contingent worker on assignment at GSK, Uxbridge, Middlesex, UK.
  • Muellerova H; Respiratory Medicine, GSK, Brentford, Middlesex, UK.
  • Compton C; Respiratory Medicine, GSK, Brentford, Middlesex, UK.
  • Jones PW; Respiratory Medicine, GSK, Brentford, Middlesex, UK.
Respir Res ; 19(1): 222, 2018 Nov 20.
Article em En | MEDLINE | ID: mdl-30453972
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by varying trajectories of decline. Information regarding the prognostic value of preventing short-term clinically important deterioration (CID) in lung function, health status, or first moderate/severe exacerbation as a composite endpoint of worsening is needed. We evaluated post hoc the link between early CID and long-term adverse outcomes. METHODS: CID was defined as ≥100 mL decrease in forced expiratory volume in 1 s (FEV1), ≥4-unit increase in St George's Respiratory Questionnaire (SGRQ) score from baseline, and/or a moderate/severe exacerbation during enrollment in two 3-year studies. Presence of CID was assessed at 6 months for the principal analysis (TORCH) and 12 months for the confirmatory analysis (ECLIPSE). Association between presence (+) or absence (-) of CID and long-term deterioration in FEV1, SGRQ, future risk of exacerbations, and all-cause mortality was assessed. RESULTS: In total, 2870 (54%; TORCH) and 1442 (73%; ECLIPSE) patients were CID+. At 36 months, in TORCH, CID+ patients (vs CID-) had sustained clinically significant worsening of FEV1 (- 117 mL; 95% confidence interval [CI]: - 134, - 100 mL; P < 0.001) and SGRQ score (+ 6.42 units; 95% CI: 5.40, 7.45; P < 0.001), and had higher risk of exacerbations (hazard ratio [HR]: 1.61 [95% CI: 1.50, 1.72]; P < 0.001) and all-cause mortality (HR: 1.41 [95% CI: 1.15, 1.72]; P < 0.001). Similar risks post-CID were observed in ECLIPSE. CONCLUSIONS: A CID within 6-12 months of follow-up was consistently associated with increased long-term risk of exacerbations and all-cause mortality, and predicted sustained meaningful loss in FEV1 and health status amongst survivors. TRIAL REGISTRATION: NCT00268216 ; NCT00292552 .
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Broncodilatadores / Volume Expiratório Forçado / Doença Pulmonar Obstrutiva Crônica / Deterioração Clínica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Broncodilatadores / Volume Expiratório Forçado / Doença Pulmonar Obstrutiva Crônica / Deterioração Clínica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article